Structure Therapeutics (NASDAQ:GPCR) Reaches New 52-Week High - Here's Why

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $28.16 and last traded at $27.00, with a volume of 1498070 shares traded. The stock had previously closed at $25.91.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on GPCR shares. William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Citigroup began coverage on Structure Therapeutics in a research note on Friday. They issued a "buy" rating and a $60.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $78.63.

Structure Therapeutics Price Performance

The stock has a market capitalization of $1.55 billion, a PE ratio of -36.49 and a beta of -1.69. The company has a 50 day moving average price of $20.68 and a 200-day moving average price of $27.21.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. As a group, equities analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd grew its stake in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after buying an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Structure Therapeutics in the 4th quarter worth about $34,000. FNY Investment Advisers LLC purchased a new position in Structure Therapeutics during the 4th quarter valued at about $40,000. Finally, Virtus ETF Advisers LLC boosted its stake in Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after acquiring an additional 455 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.